{"id":"measles-and-rubella-mr","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"10-20","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"1-3","effect":"Arthralgia (more common in rubella component)"},{"rate":"1-2","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains weakened (attenuated) strains of measles and rubella viruses that replicate in vaccinated individuals without causing disease. This triggers both humoral (antibody-mediated) and cell-mediated immune responses, providing protective immunity against natural infection with these viruses. The vaccine prevents viral replication and transmission in susceptible populations.","oneSentence":"The MR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses through live attenuated viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:27.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles"},{"name":"Prevention of rubella"}]},"trialDetails":[{"nctId":"NCT07377656","phase":"PHASE2","title":"Strengthening HPV Immunization Through EPI Leveraged Delivery","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2026-01-16","conditions":"HPV Vaccine","enrollment":115},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT03071575","phase":"PHASE4","title":"Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-03-09","conditions":"Measles, Rubella, Rubella Syndrome, Congenital","enrollment":637},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT06815835","phase":"PHASE3","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Measles, Rubella, Yellow Fever","enrollment":1530},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT04394689","phase":"PHASE1, PHASE2","title":"Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial","status":"COMPLETED","sponsor":"Micron Biomedical, Inc","startDate":"2021-05-19","conditions":"Measles, Rubella, Vaccination","enrollment":281},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT02699099","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-10","conditions":"Malaria, Malaria Vaccines","enrollment":699},{"nctId":"NCT03148990","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-11-20","conditions":"Rubella, Measles","enrollment":432},{"nctId":"NCT03680417","phase":"PHASE4","title":"Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2017-11-16","conditions":"Safety Issues, Immunogenicity","enrollment":590},{"nctId":"NCT01847872","phase":"PHASE4","title":"IPV Clinical Trial - The Gambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-07","conditions":"Poliomyelitis","enrollment":1504},{"nctId":"NCT02643433","phase":"PHASE4","title":"Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2015-08","conditions":"Measles, Rubella, Japanese Encephalitis","enrollment":1043},{"nctId":"NCT02196285","phase":"PHASE1","title":"Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2015-09","conditions":"Rubella, Measles","enrollment":30},{"nctId":"NCT02153866","phase":"PHASE4","title":"The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine","status":"UNKNOWN","sponsor":"Sichuan Center for Disease Control and Prevention","startDate":"2013-12","conditions":"Rotavirus","enrollment":2800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Measles and Rubella (MR)","genericName":"Measles and Rubella (MR)","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"The MR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of rubella.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}